Barclays’s MacroGenics MGNX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$181K Buy
62,627
+21,277
+51% +$45.4K ﹤0.01% 3748
2025
Q4
$66.6K Buy
41,350
+2,044
+5% +$3.21K ﹤0.01% 4680
2025
Q3
$66K Sell
39,306
-18,512
-32% -$30K ﹤0.01% 4707
2025
Q2
$70K Sell
57,818
-52,319
-48% -$75.9K ﹤0.01% 4654
2025
Q1
$140K Sell
110,137
-1,754
-2% -$4.58K ﹤0.01% 4266
2024
Q4
$364K Buy
111,891
+13,138
+13% +$47.3K ﹤0.01% 4015
2024
Q3
$325K Buy
98,753
+53,639
+119% +$209K ﹤0.01% 4038
2024
Q2
$192K Sell
45,114
-36,628
-45% -$357K ﹤0.01% 3603
2024
Q1
$1.2M Sell
81,742
-75,789
-48% -$1.15M ﹤0.01% 2970
2023
Q4
$1.52M Buy
157,531
+23,258
+17% +$161K ﹤0.01% 3133
2023
Q3
$626K Buy
134,273
+17,733
+15% +$88.3K ﹤0.01% 2659
2023
Q2
$623K Sell
116,540
-23,608
-17% -$146K ﹤0.01% 2612
2023
Q1
$1M Buy
140,148
+9,227
+7% +$55.6K ﹤0.01% 2728
2022
Q4
$878K Buy
130,921
+69,866
+114% +$383K ﹤0.01% 2909
2022
Q3
$211K Sell
61,055
-2,895
-5% -$11.1K ﹤0.01% 3167
2022
Q2
$189K Buy
63,950
+24,893
+64% +$131K ﹤0.01% 3460
2022
Q1
$344K Sell
39,057
-36,659
-48% -$405K ﹤0.01% 3122
2021
Q4
$1.22M Buy
75,716
+8,683
+13% +$163K ﹤0.01% 2704
2021
Q3
$1.4M Sell
67,033
-4,820
-7% -$116K ﹤0.01% 2569
2021
Q2
$1.93M Sell
71,853
-35,002
-33% -$1.03M ﹤0.01% 2222
2021
Q1
$3.4M Buy
106,855
+86,844
+434% +$2.11M ﹤0.01% 1846
2020
Q4
$458K Sell
20,011
-6,631
-25% -$153K ﹤0.01% 3291
2020
Q3
$672K Sell
26,642
-66,612
-71% -$1.82M ﹤0.01% 3007
2020
Q2
$2.6M Buy
93,254
+76,230
+448% +$1.32M ﹤0.01% 1869
2020
Q1
$98K Sell
17,024
-31,876
-65% -$289K ﹤0.01% 4816
2019
Q4
$531K Buy
48,900
+19,033
+64% +$188K ﹤0.01% 4252
2019
Q3
$381K Sell
29,867
-2,904
-9% -$41.8K ﹤0.01% 4463
2019
Q2
$556K Buy
32,771
+14,342
+78% +$246K ﹤0.01% 4226
2019
Q1
$331K Buy
+18,429
New +$319K ﹤0.01% 4443
2018
Q4
Sell
-16,507
Closed -$354K 7168
2018
Q3
$354K Buy
16,507
+13,637
+475% +$291K ﹤0.01% 4556
2018
Q2
$59K Sell
2,870
-12,232
-81% -$276K ﹤0.01% 5557
2018
Q1
$380K Buy
15,102
+6,820
+82% +$166K ﹤0.01% 4232
2017
Q4
$157K Buy
8,282
+7,253
+705% +$135K ﹤0.01% 4895
2017
Q3
$20K Sell
1,029
-5,940
-85% -$103K ﹤0.01% 5797
2017
Q2
$122K Buy
6,969
+3,430
+97% +$65.4K ﹤0.01% 4770
2017
Q1
$66K Buy
3,539
+870
+33% +$16.8K ﹤0.01% 5172
2016
Q4
$54K Sell
2,669
-5,221
-66% -$131K ﹤0.01% 5113
2016
Q3
$236K Buy
7,890
+7,860
+26,200% +$234K ﹤0.01% 3823
2016
Q2
$1K Sell
30
-1,465
-98% -$33K ﹤0.01% 6125
2016
Q1
$27K Buy
1,495
+959
+179% +$18.3K ﹤0.01% 5094
2015
Q4
$16K Sell
536
-8,830
-94% -$268K ﹤0.01% 5266
2015
Q3
$197K Buy
9,366
+8,768
+1,466% +$275K ﹤0.01% 4142
2015
Q2
$22K Sell
598
-430
-42% -$14.1K ﹤0.01% 5622
2015
Q1
$32K Sell
1,028
-17,075
-94% -$579K ﹤0.01% 5582
2014
Q4
$634K Buy
18,103
+17,850
+7,055% +$445K ﹤0.01% 3632
2014
Q3
$5K Sell
253
-182
-42% -$3.76K ﹤0.01% 7187
2014
Q2
$9K Buy
435
+194
+80% +$4.08K ﹤0.01% 6880
2014
Q1
$7K Buy
241
+150
+165% +$5.3K ﹤0.01% 7080
2013
Q4
$2K Buy
+91
New +$2.38K ﹤0.01% 7362

Other funds holding MGNX

Barclays's MGNX Position: Q1 2026 in Review

Barclays increased its MacroGenics (MGNX) stake by 51% in Q1 2026, buying an estimated $45.4K and bringing the position to 62,627 shares worth $181K. The position accounts for ﹤0.01% of the portfolio, ranked #3748.

Barclays first reported a position in MGNX in Q4 2013 and has held it in 49 quarters since. The position peaked at $3.4M in Q1 2021. 109 funds tracked by Wall St. Rank hold MGNX as of Q1 2026.

  • Barclays held 62,627 shares of MacroGenics worth $181K as of Q1 2026.
  • Barclays bought 21,277 MacroGenics shares in Q1 2026, an estimated $45.4K.
  • MacroGenics made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #3748 holding.
  • Barclays first reported a position in MacroGenics in Q4 2013 and has held it in 49 quarters since.
  • Barclays's MacroGenics position peaked at $3.4M in Q1 2021.
  • 109 funds tracked by Wall St. Rank held MacroGenics as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.